

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2022 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the 2022 third quarterly report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) (the “**2022 Third Quarterly Report**”) for the three months ended 30 September 2022 (the “**Reporting Period**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and is unaudited.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the People's Republic of China

28 October 2022

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *For identification purposes only*

1. IMPORTANT NOTICE

The board of directors (the “**Board**”) and the supervisory committee (the “**Supervisory Committee**”) of the Company and its directors, supervisors and senior management warrant that the quarterly report does not contain any false information, misleading statements or material omission and severally and jointly accept legal responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

Mr. Wu Yifang, the person in charge of the Company, Ms. Yan Jia, the Chief Financial Officer, and Ms. Li Jing, the Director of the Accounting Department (Accounting Officer) warrant the truthfulness, accuracy and completeness of the financial statements contained in the quarterly report of the Group.

The financial statements for the 2022 Third Quarterly Report of the Group has not been audited.

1. MAJOR FINANCIAL INFORMATION OF THE GROUP

(1) Major accounting information and financial indicators

Unit: Yuan Currency: RMB

Item	The Reporting Period	Increase or decrease in the Reporting Period over the corresponding period of last year (%)	From the beginning of the year to the end of the Reporting Period	Increase or decrease from the beginning of the year to the end of the Reporting Period over the corresponding period of last year (%)
Operating revenue	10,270,017,624.77	1.72	31,610,071,303.19	16.87
Net profit attributable to shareholders of the listed company ^{Note 2}	907,033,448.21	-16.20	2,454,367,005.07	-31.15
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss	997,232,651.37	10.19	2,859,070,191.44	15.51
Net cash flow generated from operating activities	1,353,331,940.11	3.38	3,173,702,942.32	5.24
Basic earnings per share (RMB/share) ^{Note 2}	0.34	-19.05	0.95	-31.65
Diluted earnings per share (RMB/share) ^{Note 2}	0.34	-19.05	0.95	-31.65
Return on weighted average net asset (%)	2.18	Decrease by 0.63 percentage points	6.14	Decrease by 3.26 percentage points

	At the end of the Reporting Period	At the end of last year	Increase or decrease at the end of the Reporting Period compared with the end of last year (%)
Total assets	104,329,254,170.04	93,293,790,957.96	11.83
Equity attributable to shareholders of the listed company	43,525,911,795.52	39,191,949,140.14	11.06

Note1: The “Reporting Period” refers to the three months period from the beginning of this quarter to the end of this quarter, the same below.

Note2: In the first three quarters of 2022, net profit after deducting extraordinary gain or loss attributable to shareholders of the listed company amounted to RMB2.859 billion, representing a period-on-period increase of 15.51%. For the first three quarters of 2022, the period-on-period decrease in net profit attributable to shareholders of listed company, basic earnings per share and diluted earnings per share were mainly due to the period-on-period decrease in extraordinary gains or losses resulting from losses on fair value changes: due to market fluctuations and other factors, the share price of BNTX held by the Group decreased at the end of the Reporting Period compared to the end of 2021, and the net effect of, among others, fair value losses resulting from changes in the share price of BNTX was approximately RMB1.1 billion.

(2) Extraordinary gain or loss items and amounts

Unit: Yuan Currency: RMB

Items	Amount of the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period
Gain or loss on disposal of non-current assets	241,952,331.61	807,062,468.09
Government grant included in profit or loss for the current period (excluding government grant closely related to the Company's normal operation, and entitled in fixed amounts or quantities on a continuous basis according to national standards)	14,078,593.93	54,242,711.99
Profit or loss arising from changes in the fair value of holding financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and investment income from disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except effective hedging business related to the Company's normal operations	-188,976,571.44	-844,068,109.46
Non-operating income and expenses other than those stated above	-15,359,584.25	-189,688,805.02
Other profit or loss items that fall within the meaning of extraordinary gain or loss	-44,020,277.96	-86,710,962.72
Less: Effect of income tax	-56,844,568.85	-164,053,754.94
Impact on non-controlling interests (after tax)	-41,029,126.20	18,513,265.69
Total	-90,199,203.16	-404,703,186.37

(3) Changes in the principal accounting information and financial indicators and reasons for the changes

Name of item	Ratio of change (%)	Main Reason
Net profit attributable to shareholders of listed company for the first three quarters	-31.15	In the first three quarters of 2022, net profit after deducting extraordinary gain or loss attributable to shareholders of listed company amounted to RMB2.859 billion, representing a period-on-period increase of 15.51%. For the first three quarters of 2022, the period-on-period decrease in net profit attributable to shareholders of listed company, basic earnings per share and diluted earnings per share were mainly due to the period-on-period decrease in extraordinary gains or losses resulting from losses on fair value changes: due to market fluctuations and other factors, the share price of BNTX held by the Group decreased at the end of the Reporting Period compared to the end of 2021, and the net effect of, among others, fair value losses resulting from changes in the share price of BNTX was approximately RMB1.1 billion.
Basic earnings per share for the first three quarters (RMB yuan/share)	-31.65	Same as above
Diluted earnings per share for the first three quarters (RMB yuan/share)	-31.65	Same as above

2. SHAREHOLDER INFORMATION

- (1) Total number of holders of ordinary shares and holders of preference shares with resumed voting rights, and the shareholding status of the Top 10 shareholders

Unit: Share

Total number of holders of ordinary shares as at the end of the Reporting Period	314,459	Total number of holders of preference shares with resumed voting rights as at the end of the Reporting Period (if any)	N/A			
The shareholding status of the Top 10 shareholders						
Name of shareholders	Capacity	Shareholding	Percentage of shareholding (%)	Number of restricted shares held	Shares pledged, marked or locked up	
					Status	Number
Fosun High Technology	Domestic non-state owned legal entity	892,008,655 ^{Note 1}	33.41	0	None	0
HKSCC NOMINEES LIMITED ^{Note 2}	Unknown	551,360,830	20.65	0	Unknown	—
HONG KONG SECURITIES CLEARING COMPANY LIMITED ^{Note 3}	Others	52,323,263	1.96	0	None	0
PERSEVERANCE ASSET MANAGEMENT L.L.P. — GAO YI LINGSHAN NO. 1 YUANWANG FUND* (高毅鄰山1號遠望基金)	Securities investment fund	47,619,047	1.78	47,619,047	None	0
CHINA SECURITIES FINANCE CORPORATION LIMITED* (中國證券金融股份有限公司)	Others	38,736,079	1.45	0	None	0
UBS AG	Qualified Foreign Institutional Investor	21,594,745	0.81	20,095,238	None	0
Qiu Mingjing (邱明靜)	Domestic natural person	17,690,000	0.66	0	None	0
BANK OF CHINA LIMITED — CHINA MERCHANTS NATIONAL SECURITIES BIOMEDICAL INDEX CLASSIFIED SECURITIES INVESTMENT FUND* (招商國證生物醫藥指數分級證券投資基金)	Securities investment fund	16,882,039	0.63	0	None	0
INDUSTRIAL AND COMMERCIAL BANK OF CHINA — SSE INDEX 50 TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND	Securities investment fund	9,181,755	0.34	0	None	0
CHINA CONSTRUCTION BANK CORPORATION — E FUND CSI 300 MEDICAL AND HEALTHCARE TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND (易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	Securities investment fund	7,974,745	0.30	0	None	0

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type of shares	Number
Fosun High Technology	892,008,655	RMB ordinary shares	892,008,655
HKSCC NOMINEES LIMITED ^{Note 2}	551,360,830	Overseas listed foreign shares	551,360,830
HONG KONG SECURITIES CLEARING COMPANY LIMITED ^{Note 3}	52,323,263	RMB ordinary shares	52,323,263
CHINA SECURITIES FINANCE CORPORATION LIMITED* (中國證券金融股份有限公司)	38,736,079	RMB ordinary shares	38,736,079
Qiu Mingjing (邱明靜)	17,690,000	RMB ordinary shares	17,690,000
BANK OF CHINA LIMITED — CHINA MERCHANTS NATIONAL SECURITIES BIOMEDICAL INDEX CLASSIFIED SECURITIES INVESTMENT FUND* (招商國證生物醫藥指數分級證券投資基金)	14,551,908	RMB ordinary shares	14,551,908
INDUSTRIAL AND COMMERCIAL BANK OF CHINA — SSE INDEX 50 TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND	9,181,755	RMB ordinary shares	9,181,755
CHINA CONSTRUCTION BANK CORPORATION — E FUND CSI 300 MEDICAL AND HEALTHCARE TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND* (易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	7,974,745	RMB ordinary shares	7,974,745
BANK OF SHANGHAI CO., LTD. — YINHUA CSI INNOVATIVE DRUG INDUSTRY TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND* (銀華中證創新藥產業交易型開放式指數證券投資基金)	5,059,095	RMB ordinary shares	5,059,095
CHINA MERCHANTS BANK CO., LTD. — XINGYE INCOME ENHANCEMENT BOND SECURITIES INVESTMENT FUND* (興業收益增強債券型證券投資基金)	3,730,000	RMB ordinary shares	3,730,000
Description of the related relationship or concerted action of the above shareholders	The Company does not know whether any related relationship or concerted action exists between the abovementioned shareholders of tradable shares.		
Status description of Top 10 shareholders and Top 10 unrestricted shareholders participating in securities margin trading and refinancing business (if any)	Qiu Mingjing (邱明靜) holds 17,690,000 shares, all of which are held through securities margin trading account.		

Note 1: Representing A shares only;

Note 2: HKSCC NOMINEES LIMITED, i.e. Hong Kong Securities Clearing Company Nominees Limited, is holding shares on behalf of multiple clients (shares held by it at the end of the Reporting Period includes an aggregate of 77,533,500 H shares of the Company held by Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司) (“**Fosun High Technology**”) and its controlling shareholder, Fosun International Limited, through it, representing approximately 2.90% of the total share capital of the Company as at the end of the Reporting Period);

Note 3: HONG KONG SECURITIES CLEARING COMPANY LIMITED is the nominee holder of the RMB ordinary shares under Shanghai-Hong Kong Stock Connect.

3. OTHER REMINDER

The investors are reminded to pay attention to other significant information concerning the Company's operations during the Reporting Period

(I) Overview of operating results

In the first three quarters of 2022, the Group adhered to the implementation of the “4IN” strategy and has kept focusing on the development of business lines of various divisions, and continued to advance its internationalization strategy.

In the first three quarters of 2022, the Group's operating revenue and net profit after deducting extraordinary gain or loss attributable to shareholders of the listed company continued to grow. In the first three quarters, the operating revenue of the Group amounted to RMB31.610 billion, representing a period-on-period increase of 16.87%; net profit attributable to shareholders of the listed company after deducting extraordinary profit or loss amounted to RMB2.859 billion, representing a period-on-period increase of 15.51%; net cash flow from operating activities amounted to RMB3.174 billion, representing a period-on-period increase of 5.24%. Due to market fluctuations and other factors, the price of shares of BNTX held by the Group as of the end of the Reporting Period declined as compared with the end of 2021, and the net effect of fair value loss due to changes in the share price of BNTX was approximately RMB1.1 billion. As a result of the loss from change in fair value of financial assets held by the Group, the Group's extraordinary profit or loss for the first three quarters was RMB-405 million, representing a period-on-period decrease of RMB1.494 billion. Due to the period-on-period decrease in extraordinary gain or loss, the Group's net profit attributable to shareholders of the listed company for the first three quarters was RMB2.454 billion, representing a period-on-period decrease of 31.15%.

In the first three quarters of 2022, the total R&D expenditure of the Group amounted to RMB3.761 billion, representing a period-on-period increase of 19.36%. In particular, the R&D expenses amounted to RMB2.849 billion, representing a period-on-period increase of RMB435 million or 18.02%.

Since July 2022, the Group's main operations and product research and development progress are as follows:

1. *Full commercialisation of the Azvudine jointly developed by the Company and Genuine Biotech*

In July 2022, Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) (“**Fosun Pharmaceutical Industrial**”), a controlling subsidiary of the Company, entered a strategic cooperation with Henan Genuine Biotech Co., Ltd.* (河南真實生物科技有限公司), pursuant to which both parties will jointly develop Azvudine, which will be exclusively commercialised by Fosun Pharmaceutical Industrial. The scope of cooperation includes the treatment and prevention of COVID-19 and AIDS.

Azivudine tablets is the first oral small molecule COVID-19 drug independently developed and approved for market launch in China. In August 2022, Azvudine tablets were included in the Diagnosis and Treatment Guideline for COVID-19 (9th Edition)* (《新型冠狀病毒肺炎診療方案(第九版)》). In September 2022, Azvudine tablets were also included in the Adjusted List of Declared Pharmaceutical Products Passed with Formal Examination in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance for 2022* (《2022年國家基本醫療保險、工傷保險和生育保險藥品目錄調整通過形式審查的申報藥品名單》). As at the date of this report, Azivudine tablets have been included in procurement platform of medical insurance system in 31 provinces, autonomous regions and municipalities across the country. The procurement price of Azivudine tablets on the procurement platform of medical insurance system is RMB270 per bottle (35 tablets per bottle and 1mg per tablet).

In order to enhance the market availability of Azvudine tablets, Fosun Pharmaceutical Industrial has signed a strategic cooperation agreement with Sinopharm Group Co. Ltd.* (國藥控股股份有限公司), a leading enterprise in distribution of pharmaceutical products in China, for the purpose of accelerating the process of making Azvudine tablets available in different distribution channels nationwide. As at the date of this report, Azvudine tablets have successively supplied to regions such as Xinjiang, Hainan, Henan, Yunnan and Inner Mongolia, contributing to the COVID-19 prevention and control.

2. *The development, registration and BD progress of our products*

YI KAI DA (Ejilunsai injection) is the first product of Fosun Kite Biotechnology Co., Ltd.* (復星凱特生物科技有限公司), a joint venture, that is based on the technology transfer of Yescarta, a CAR-T-cell therapy product introduced from Kite Pharma (KP EU C.V.), and is authorised to carry out localized production in China. The application for market launch and registration of products for the third indication (for the treatment of adult patients who have failed first-line immunochemotherapy or relapsed large B-cell

lymphoma within 12 months after first-line immunochemotherapy) (r/r LBCL) of YI KAI DA was accepted in October 2022 and was included in the list of priority review products.

As of the date of this report, the application for market launch of three indications (squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC) and esophageal squamous cell carcinoma (ESCC)) of HANSIZHUANG (serplulimab Injection) that is independently developed by the Group has been accepted successively by the National Medical Products Administration of the People's Republic of China* (中華人民共和國國家藥品監督管理局). In particular, the results of phase III clinical trial of HANSIZHUANG (serplulimab Injection) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC) were published in September 2022 in the Journal of the American Medical Association (i.e. JAMA, Factors of Impact: 157.3), one of the four top medical journals in the world.

Furthermore, HAN QU YOU (trastuzumab injection), a product independently developed by the Group and licensing to Cipla Limited with its subsidiaries, was approved for market launch in Australia in July 2022. The product was approved for indications include ① HER2-positive early-stage breast cancer, ② HER2-positive locally advanced breast cancer, ③ HER2-overexpressing metastatic breast cancer, and ④ HER2-positive advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. So far, the approved indications of the product in Australia have covered all approved indications of the branded drug in that country.

In 2022, the vaccination of Comirnaty (mRNA COVID-19 Vaccine) and the process of registration of new dosage in Hong Kong, Macau and Taiwan have been continued. In particular, the vaccination of dosage for infants was approved in August 2022 for infants aged 6 months to 4 years old in Taiwan, China while the vaccination of dosage for children has been approved in May 2022. Dosage for children and infants were approved for emergency use in Hong Kong, China in September 2022. Dosage for infants was also approved by Macau, China with advance permission as an imported vaccine in October 2022 while the vaccination of dosage for children has been approved in April 2022. The emergency use of bivalent vaccines against Omicron BA.4/BA.5 in Taiwan, China was approved in October 2022, and the application for emergency use / special permission for import of the vaccines has been filed in Hong Kong and Macau respectively.

In terms of product and business cooperation, in September 2022, Fosun Pharmaceutical Industrial entered into an exclusive sales agency and development agreement with Neovii Pharmaceuticals AG, pursuant to which Fosun Pharmaceutical Industrial is entitled to the exclusive license to sell and develop its immune inhibitor Grafalon (anti-human T lymphocyte rabbit immunoglobulin) in China. In the same month, Fosun Pharmaceutical Industrial also entered into a license contract with Jiangsu Carephar Pharmaceutical Co., Ltd.* (江蘇柯菲平醫藥股份有限公司), pursuant to which both parties will enter

into a global collaboration to co-develop Keverprazan Hydrochloride, which will be exclusively commercialized by Fosun Pharmaceutical Industrial. The collaboration scope includes all available indications of Keverprazan Hydrochloride oral drug product and common injection. In addition, in October 2022, the Company and China Resources Pharmaceutical Group Limited* (華潤醫藥控股有限公司) entered into a strategic cooperation, pursuant to which both parties will strengthen their global layout and industrial development in the relevant fields through strategic and business cooperation focusing on innovative drugs, biological drugs, medical devices and others in big health field.

3. *Enhanced ESG (environmental, social and governance) grading*

The Company was ranked among the top 40 in the first Fortune China ESG Influence List* (《財富》中國ESG影響力榜單) in August 2022. In October 2022, the Company's MSCI ESG rating was further upgraded from grade BBB to grade A, which outperformed other industry peers in China.

(II) Financing

1. In July 2022, the Company completed the non-public issuance of A shares, issuing 106,756,666 new A shares and raising a total of RMB4.484 billion. Upon the completion of the non-public issuance of A shares, the total share capital of the Company increased from 2,562,898,545 shares to 2,669,655,211 shares.
2. In July 2022, the National Association of Financial Market Institutional Investors accepted the registration of the Company's super and short-term commercial papers with a registered amount of RMB6 billion. The registered amount is valid for 2 years from 14 July 2022. The Company can issue in tranches within the effective period of the registration.
3. In August 2022, the National Association of Financial Market Institutional Investors accepted the registration of the Company's medium-term notes with a registered amount of RMB4 billion. The registered amount is valid for 2 years from 12 August 2022. The Company can issue the notes in tranches within the effective period of the registration.

4. APPENDICES

4.1 Audited report

Not applicable

4.2 Financial statements

Consolidated Balance Sheet

30 September 2022

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2022	31 December 2021
Current assets:		
Cash and bank balances	14,867,225,319.98	10,308,157,065.27
Financial assets held for trading	1,778,099,831.41	4,241,069,085.61
Bills receivable	22,906,765.81	16,227,279.63
Trade receivable	7,252,224,411.52	6,029,232,584.33
Receivables financing	554,156,181.44	427,883,962.35
Prepayments	1,720,614,589.13	1,738,129,227.24
Other receivables	627,106,023.29	842,558,024.99
Including: Dividends receivable	19,678,020.08	19,678,020.08
Inventories	6,772,959,245.40	5,472,315,468.74
Assets held for sale	419,577,812.77	463,704,813.34
Non-current assets due within one year	138,558,166.68	188,839,750.00
Other current assets	389,505,102.62	696,516,028.18
Total current assets	34,542,933,450.05	30,424,633,289.68
Non-current assets:		
Long-term receivables	81,845,530.56	77,395,288.47
Long-term equity investments	23,190,492,783.67	22,683,713,418.51
Other equity instrument investments	17,176,545.49	29,915,556.21
Other non-current financial assets	1,798,931,480.82	1,206,488,930.44
Fixed assets	10,145,143,384.87	8,918,876,913.76
Construction in progress	3,893,035,544.64	3,617,704,520.01
Right-of-use assets	809,407,754.33	747,347,175.47
Intangible assets	12,055,501,647.58	10,276,254,397.82
Development expenditures	3,400,430,394.01	3,156,906,315.18
Goodwill	10,698,415,763.69	9,399,987,036.57
Long-term deferred expenditures	525,392,244.14	475,236,970.94
Deferred tax assets	375,480,463.13	265,589,462.47
Other non-current assets	2,795,067,183.06	2,013,741,682.43
Total non-current assets	69,786,320,719.99	62,869,157,668.28
Total assets	104,329,254,170.04	93,293,790,957.96

Consolidated Balance Sheet (Continued)
30 September 2022

Items	30 September 2022	31 December 2021
Current liabilities:		
Short-term loans	11,829,019,528.42	9,420,129,313.44
Bills payable	827,754,111.21	548,388,304.87
Trade payable	4,623,985,005.37	4,515,272,864.69
Contract liabilities	1,268,442,362.04	1,150,274,106.91
Wages payable	1,285,108,235.72	1,295,840,246.83
Tax payable	905,204,493.71	727,522,247.25
Other payables	4,720,682,046.45	4,996,429,841.33
Including: Dividends payable	33,436,354.05	28,831,507.09
Non-current liabilities due within one year	5,425,254,226.79	5,127,487,867.14
Other current liabilities	376,076,539.94	1,528,600,495.19
Total current liabilities	31,261,526,549.65	29,309,945,287.65
Non-current liabilities:		
Long-term loans	11,706,969,842.17	6,694,183,385.90
Bonds payable	499,315,312.49	2,354,886,327.49
Lease liabilities	671,605,121.87	648,360,205.12
Long-term payables	224,922,743.84	245,793,336.10
Long-term wages payable	43,952,400.00	54,425,000.00
Deferred income	530,914,214.07	512,806,418.38
Deferred tax liabilities	3,391,285,022.56	3,129,746,176.23
Other non-current liabilities	2,772,424,772.92	1,968,080,369.57
Total non-current liabilities	19,841,389,429.92	15,608,281,218.79
Total liabilities	51,102,915,979.57	44,918,226,506.44
Owners' Equity (or shareholders' equity):		
Share Capital	2,669,655,211.00	2,562,898,545.00
Capital reserve	16,961,552,602.67	14,029,021,356.33
Other comprehensive income	-1,023,201,091.49	-1,265,831,690.95
Surplus reserve	2,826,306,841.05	2,826,306,841.05
Retained profits	22,091,598,232.29	21,039,554,088.71
Total equity attributable to the owners (or shareholders) of the parent company	43,525,911,795.52	39,191,949,140.14
Non-controlling interests	9,700,426,394.95	9,183,615,311.38
Total owners' equity (or shareholders' equity)	53,226,338,190.47	48,375,564,451.52
Total liabilities and owners' equity (or shareholders' equity)	104,329,254,170.04	93,293,790,957.96

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Yan Jia

*Director of
the Accounting Department:*
Li Jing

Consolidated Income Statement
January — September 2022

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2022 (Jan–Sept)	First three quarters of 2021 (Jan–Sept) (Restated)
I. Total operating revenue	31,610,071,303.19	27,048,280,045.37
Including: Operating revenue	31,610,071,303.19	27,048,280,045.37
II. Total operating costs	29,398,980,915.03	25,425,602,296.23
Including: Operating costs	16,907,922,929.37	13,636,234,949.39
Tax and surcharges	164,764,944.45	172,834,094.24
Selling expenses	6,482,786,801.90	6,558,523,039.78
General and administrative expenses	2,617,341,150.70	2,250,761,651.93
Research and development expenses	2,848,545,845.20	2,413,787,522.55
Finance costs	377,619,243.41	393,461,038.34
Including: Interest expenses	697,287,664.37	632,128,241.84
Interest income	198,218,330.73	174,506,420.51
Plus: Other gains	247,140,432.71	178,525,743.15
Investment income (“–” indicating loss)	3,053,470,757.55	1,849,134,316.25
Including: Investment income from associates and joint ventures	1,220,658,910.22	1,321,105,089.92
Gains from changes in fair value (“–” indicating loss)	–1,930,779,093.73	1,322,786,570.87
Credit impairment losses (“–” indicating loss)	–34,904,497.28	–20,342,785.40
Asset impairment losses (“–” indicating loss)	–93,589,712.36	–246,291,983.30
Gains from disposal of assets (“–” indicating loss)	140,104,537.54	–7,272,716.06
III. Operating profit (“–” indicating loss)	3,592,532,812.59	4,699,216,894.65
Plus: Non-operating revenue	16,763,161.55	23,103,255.88
Less: Non-operating expenses	206,451,966.56	56,112,339.40
IV. Total profit (“–” indicating total loss)	3,402,844,007.58	4,666,207,811.13
Less: Income tax expenses	611,539,705.21	731,265,667.91
V. Net profit (“–” indicating net loss)	2,791,304,302.37	3,934,942,143.22
(i) Classification according to the continuity of operation		
1. Net profit from continuing operation (“–” indicating net loss)	2,791,304,302.37	3,934,942,143.22
2. Net profit from discontinued operation (“–” indicating net loss)	—	—
(ii) Classification according to ownership		
1. Net profit attributable to the shareholders of the parent company (“–” indicating net loss)	2,454,367,005.07	3,564,733,323.53
2. Profit or loss attributable to non-controlling interests (“–” indicating net loss)	336,937,297.30	370,208,819.69

Consolidated Income Statement (Continued)

January — September 2022

Items	First three quarters of 2022 (Jan–Sept)	First three quarters of 2021 (Jan–Sept) (Restated)
VI. Other comprehensive income, net of tax	450,398,730.53	–176,803,630.32
(1) Other comprehensive income attributable to the owners of the parent company, net of tax	275,772,725.20	–137,674,789.51
(i) Other comprehensive income not reclassified subsequently to profit or loss	–10,194,957.34	12,931,612.65
1. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit or loss	—	10,724,984.42
2. Changes in fair value of other equity instrument investments	–10,194,957.34	2,206,628.23
(ii) Other comprehensive income reclassified subsequently to profit or loss	285,967,682.54	–150,606,402.16
1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss	–80,381,297.42	55,782,620.54
2. Difference in translation of foreign currency	366,348,979.96	–206,389,022.70
(2) Other comprehensive income attributable to non-controlling interests, net of tax	174,626,005.33	–39,128,840.81
VII. Total comprehensive income	3,241,703,032.90	3,758,138,512.90
(1) Total comprehensive income attributable to the owners of the parent company	2,730,139,730.27	3,427,058,534.02
(2) Total comprehensive income attributable to non-controlling interests	511,563,302.63	331,079,978.88
VIII. Earnings per share:		
(1) Basic earnings per share (RMB yuan/share)	0.95	1.39
(2) Diluted earnings per share (RMB yuan/share)	0.95	1.39

Note: The items “Operating costs” and “Selling expenses” for the first three quarters of 2021 (Jan–Sept) have been restated due to adjustments in the presentation of transportation costs.

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Yan Jia

*Director of
the Accounting Department:*
Li Jing

Consolidated Statement of Cash Flow
January — September 2022

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2022 (Jan–Sept)	First three quarters of 2021 (Jan–Sept) (Restated)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	31,878,732,648.02	27,275,297,002.49
Refund of taxes and levies	569,333,235.34	372,195,921.22
Other cash received relating to operating activities	1,267,221,815.10	594,268,748.90
Sub-total of cash inflow generated from operating activities	33,715,287,698.46	28,241,761,672.61
Cash paid for purchasing goods and receiving services	15,832,651,743.63	12,310,745,026.63
Cash paid to and on behalf of employees	6,851,289,984.40	5,242,521,416.82
Cash paid for all types of taxes	1,814,613,701.09	1,724,762,282.96
Other cash paid relating to operating activities	6,043,029,327.02	5,947,954,656.75
Sub-total of cash outflow generated from operating activities	30,541,584,756.14	25,225,983,383.16
Net cash flow generated from operating activities	3,173,702,942.32	3,015,778,289.45
II. Cash flow generated from investing activities:		
Cash received from disposal of investments	1,999,539,052.44	966,694,648.76
Cash received from returns on investments	781,242,948.26	644,402,558.56
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	139,770,144.72	94,882,070.57
Net cash received from disposal of subsidiaries and other operating segments	704,493,200.43	603,036,236.72
Other cash received relating to investing activities	282,767,712.51	237,180,435.62
Sub-total of cash inflow generated from investing activities	3,907,813,058.36	2,546,195,950.23
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	4,475,953,173.92	3,501,556,905.05
Cash paid for investments	862,199,305.24	635,740,597.92
Net cash paid for acquisition of subsidiaries and other operating segments	1,185,925,636.44	123,510,240.02
Other cash paid relating to investing activities	1,586,146,225.74	870,790,578.15
Sub-total of cash outflow generated from investing activities	8,110,224,341.34	5,131,598,321.14
Net cash flow generated from investing activities	-4,202,411,282.98	-2,585,402,370.91

Consolidated Statement of Cash Flow (*Continued*)

January — September 2022

Items	First three quarters of 2022 (Jan–Sept)	First three quarters of 2021 (Jan–Sept) (Restated)
III. Cash flow generated from financing activities:		
Cash received from capital contribution	4,576,106,656.28	793,353,791.29
Including: Cash received by subsidiaries from investments of non-controlling interests	119,907,907.76	793,353,791.29
Cash received from borrowings	24,735,091,427.40	21,253,536,266.29
Other cash received relating to financing activities	543,599,653.56	275,345,953.60
Sub-total of cash inflow generated from financing activities	29,854,797,737.24	22,322,236,011.18
Cash paid for debts settlement	20,782,333,623.69	19,874,634,563.23
Cash paid for the distribution of dividends, profits or interests	2,250,716,593.12	1,847,652,871.76
Including: Dividends and profits paid by subsidiaries to non-controlling interests	137,446,317.40	116,663,427.22
Other cash paid relating to financing activities	1,878,618,427.59	1,344,638,932.39
Sub-total of cash outflow generated from financing activities	24,911,668,644.40	23,066,926,367.38
Net cash flow generated from financing activities	4,943,129,092.84	-744,690,356.20
IV. Effects of exchange rate fluctuations on cash and cash equivalents	319,317,772.15	-75,845,764.86
V. Net increase of cash and cash equivalents	4,233,738,524.33	-390,160,202.52
Plus: Opening balance of cash and cash equivalents	6,450,650,095.59	7,324,881,260.28
VI. Closing balance of cash and cash equivalents	10,684,388,619.92	6,934,721,057.76

Note: The items “Cash paid for purchasing goods and receiving services” and “Other cash paid relating to operating activities” for the first three quarters of 2021 (Jan–Sept) had been restated due to the adjustment of transportation costs.

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Yan Jia

*Director of
the Accounting Department:*
Li Jing

Balance Sheet of the Parent Company
30 September 2022

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2022	31 December 2021
Current assets:		
Cash and bank balances	2,291,315,370.69	768,036,013.63
Other receivables	5,024,486,397.71	6,643,892,558.26
Including: Dividends receivable	182,342,267.01	182,342,267.01
Assets held for sale	419,577,812.77	419,577,812.77
Non-current assets due within one year	2,944,830,000.00	2,938,030,000.00
Other current assets	694,696,057.92	373,967,911.98
Total current liabilities	11,374,905,639.09	11,143,504,296.64
Non-current assets:		
Other non-current financial assets	119,972,858.05	66,942,097.48
Long-term equity investments	31,916,316,405.84	29,614,377,179.77
Fixed assets	6,959,421.57	6,875,642.89
Intangible assets	1,711,958.00	2,085,143.02
Other non-current assets	4,928,799,284.01	4,791,720,146.05
Total non-current assets	36,973,759,927.47	34,482,000,209.21
Total assets	48,348,665,566.56	45,625,504,505.85
Current liabilities:		
Short-term loans	3,937,155,533.67	3,494,083,642.11
Wages payable	64,085,007.13	103,445,897.10
Tax payable	35,858,910.91	114,469,581.93
Other payables	2,528,200,014.81	3,319,990,211.62
Non-current liabilities due within one year	3,404,159,455.27	2,258,231,346.51
Other current liabilities	207,220,137.21	1,213,795,137.21
Total current liabilities	10,176,679,059.00	10,504,015,816.48
Non-current liabilities:		
Long-term loans	3,483,200,000.00	2,802,000,000.00
Bonds payable	499,315,312.49	2,354,886,327.49
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79
Total non-current liabilities	5,133,534,186.28	6,307,905,201.28
Total liabilities	15,310,213,245.28	16,811,921,017.76

Balance Sheet of the Parent Company (Continued)
30 September 2022

Items	30 September 2022	31 December 2021
Owners' Equity (or shareholders' equity):		
Share capital	2,669,655,211.00	2,562,898,545.00
Capital reserve	18,702,293,366.09	14,363,581,643.18
Other comprehensive income	-154,718,836.55	-41,330,954.39
Surplus reserve	1,281,449,272.50	1,281,449,272.50
Retained profits	10,539,773,308.24	10,646,984,981.80
Total owners' equity (or shareholders' equity)	33,038,452,321.28	28,813,583,488.09
Total liabilities and owners' equity (or shareholders' equity)	48,348,665,566.56	45,625,504,505.85

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Yan Jia

*Director of
the Accounting Department:*
Li Jing

Income Statement of the Parent Company

January — September 2022

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2022 (Jan–Sept)	First three quarters of 2021 (Jan–Sept)
I. Operating revenue	4,945,815.71	3,008,397.82
Less: Tax and surcharges	107,275.69	278,390.00
General and administrative expenses	145,027,230.71	118,162,462.31
Finance costs	300,817,176.40	165,520,695.01
Including: Interest expenses	362,801,318.08	397,761,921.79
Interest income	102,765,537.09	239,143,215.24
Plus: Other income	—	9,945.70
Investment income (“–” indicating loss)	1,698,506,375.22	1,889,225,507.94
Including: Investment income from associates and joint ventures	1,547,191,990.72	1,542,733,736.00
Gains from changes in fair value (“–” indicating loss)	55,308,060.53	–6,232,713.61
Asset impairment losses (“–” indicating loss)	—	–37,545,685.54
Gains from disposal of assets (“–” indicating loss)	42,141.02	56,217.25
II. Operating profit (“–” indicating loss)	1,312,850,709.68	1,564,560,122.24
Plus: Non-operating revenue	—	—
Less: Non-operating expenses	8,475,472.00	667,607.00
III. Total profit (“–” indicating total loss)	1,304,375,237.68	1,563,892,515.24
Less: Income tax expenses	9,264,049.75	—
IV. Net profit (“–” indicating net loss)	1,295,111,187.93	1,563,892,515.24
(i) Net profit from continuing operation (“–” indicating net loss)	1,295,111,187.93	1,563,892,515.24
(ii) Net profit from discontinued operation (“–” indicating net loss)	—	—
V. Other comprehensive income, net of tax	–80,245,756.42	67,527,499.18
(i) Other comprehensive income not reclassified subsequently to profit or loss	—	10,724,984.42
1. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit or loss	—	10,724,984.42
(ii) Other comprehensive income reclassified subsequently to profit or loss	–80,245,756.42	56,802,514.76
1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss	–80,245,756.42	56,802,514.76
VI. Total comprehensive income	1,214,865,431.51	1,631,420,014.42
VII. Earnings per share:		
(i) Basic earnings per share (RMB yuan/share)	N/A	N/A
(ii) Diluted earnings per share (RMB yuan/share)	N/A	N/A

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Yan Jia

*Director of
the Accounting Department:*
Li Jing

Statement of Cash Flow of the Parent Company
January — September 2022

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2022 (Jan-Sept)	First three quarters of 2021 (Jan-Sept)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	3,159,560.00	4,164,646.64
Refund of taxes and levies	7,368,673.11	596,600.22
Other cash received relating to operating activities	222,884,874.82	144,454,962.87
Sub-total of cash inflow generated from operating activities	233,413,107.93	149,216,209.73
Cash paid to and on behalf of employees	149,621,854.33	119,085,528.44
Cash paid for all types of taxes	109,405,888.12	579,753.07
Other cash paid relating to operating activities	60,924,892.97	33,178,860.54
Sub-total of cash outflow generated from operating activities	319,952,635.42	152,844,142.05
Net cash flow generated from operating activities	-86,539,527.49	-3,627,932.32
II. Cash flow generated from investing activities:		
Cash received from disposal of investments	2,277,299.97	351,401,741.60
Cash received from returns on investments	636,723,486.51	741,781,310.31
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	—	27,000.00
Net cash received from disposal of subsidiaries and other operating segments	319,220,000.00	—
Sub-total of cash inflow generated from investing activities	958,220,786.48	1,093,210,051.91
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	1,642,660.00	2,029,918.54
Cash paid for investments	1,808,653,463.40	376,871,803.91
Sub-total of cash outflow generated from investing activities	1,810,296,123.40	378,901,722.45
Net cash flow generated from investing activities	-852,075,336.92	714,308,329.46
III. Cash flow generated from financing activities:		
Cash received from capital contribution	4,456,198,748.52	—
Cash received from borrowings	7,983,530,136.37	11,802,833,869.75
Other cash received relating to financing activities	11,176,223,271.63	8,815,916,706.21
Sub-total of cash inflow generated from financing activities	23,615,952,156.52	20,618,750,575.96
Cash paid for debts settlement	8,810,769,536.37	10,522,276,200.00
Cash paid for the distribution of dividends, profits or interest	1,810,681,524.43	1,538,277,741.68
Other cash paid relating to financing activities	10,339,374,851.01	8,981,382,378.19
Sub-total of cash outflow generated from financing activities	20,960,825,911.81	21,041,936,319.87
Net cash flow generated from financing activities	2,655,126,244.71	-423,185,743.91
IV. Effects of exchange rate fluctuations on cash and cash equivalents	2,267,976.76	-149,574.83
V. Net increase of cash and cash equivalents	1,718,779,357.06	287,345,078.40
Plus: Opening balance of cash and cash equivalents	77,536,013.63	48,610,650.37
VI. Closing balance of cash and cash equivalents	1,796,315,370.69	335,955,728.77

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Yan Jia

*Director of
the Accounting Department:*
Li Jing

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

28 October 2022

* For identification purposes only